James M. Frates
Chief Financial Officer at Amylyx Pharmaceuticals. Based in Cambridge, Massachusetts.
- Rank
- 8733rd of 14,644
- Companies held
- 1
- Largest holding
- AMLX, 100.0% of total
- Latest SEC filing
- Nov 10, 2026
What the $10.1M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX Common Stock | Directly | 233,625 | $26.20 | $6.1M | 60.7% | Form 4, Nov 10, 2026 |
| Amylyx Pharmaceuticals AMLX Common Stock | Through Trust | 100,000 | $26.20 | $2.6M | 26.0% | Form 4, Nov 9, 2026 |
| Amylyx Pharmaceuticals AMLX Common Stock | Through Trust | 40,000 | $26.20 | $1.0M | 10.4% | Form 4, Nov 9, 2026 |
| Amylyx Pharmaceuticals AMLX Common Stock | Through Trust | 11,072 | $26.20 | $290K | 2.9% | Form 4, Nov 9, 2026 |
Share counts are the amounts James M. Frates reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Sold | AMLX | 12,800 | $30.32 | $388K | View |
| Nov 10, 2026 | Sold | AMLX | 7,200 | $30.97 | $223K | View |
| Nov 9, 2026 | Sold | AMLX | 7,700 | $29.39 | $226K | View |
| Nov 9, 2026 | Sold | AMLX | 12,300 | $30.11 | $370K | View |
| Sep 10, 2026 | Sold | AMLX | 9,768 | $32.27 | $315K | View |
| Sep 10, 2026 | Sold | AMLX | 1,042 | $33.23 | $35K | View |
| Mar 2, 2026 | Sold | AMLX | 7,909 | $14.52 | $115K | View |
| Feb 2, 2026 | Sold | AMLX | 3,557 | $14.65 | $52K | View |
| Jan 6, 2026 | Sold | AMLX | 3,326 | $11.11 | $37K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 8730 | Chrysostomos L. Nikias Director, Synopsys. Mountain View, CA | $10.1M |
| 8731 | James Robert Foster SVP, Finance and CFO, ATI. Dallas, TX | $10.1M |
| 8732 | Justin Krause SVP FINANCE AND CONTROLLER, Sezzle. Minneapolis, MN | $10.1M |
| 8733 | James M. Frates Chief Financial Officer, Amylyx Pharmaceuticals. Cambridge, MA | $10.1M |
| 8734 | Louis Todd Borgmann CHIEF EXECUTIVE OFFICER, Calumet. Indianapolis, IN | $10.1M |
| 8735 | John F. Runkel Jr. GC & Corporate Secretary, Synopsys. Sunnyvale, CA | $10.1M |
| 8736 | David A. Buzen Head of Asset Management*, Assured Guaranty | $10.1M |
Other Amylyx Pharmaceuticals insiders
All AMLX insiders- Joshua B. Cohen$92.0MCo-Chief Executive Officer. #1600 overall
- Justin B. Klee$92.0MCo-Chief Executive Officer. #1601 overall
- George M. Milne Jr.$20.5MDirector. #4876 overall
- Camille L. Bedrosian$7.3MChief Medical Officer. #9587 overall
- Margaret Olinger$7.2MChief Commercial Officer. #11149 overall
- Patrick D. Yeramian$5.4MChief Medical Officer. #13735 overall
Questions
How much stock does James M. Frates own?
James M. Frates holds $10,079,061 in listed stock based on SEC filings and current prices, mostly Amylyx Pharmaceuticals (AMLX). That ranks 8733rd on the Stock Rich List.
Is this James M. Frates's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did James M. Frates last buy or sell stock?
The most recent open-market trade on file is a sale of 12,800 AMLX shares on Nov 10, 2026 at $30.32.